NCT05775380 (PREVALENT) is a Phase 4 clinical trial of Pioglitazone 45 mg in Myocardial Reperfusion Injury, sponsored by University of Campinas, Brazil.

Who is sponsoring NCT05775380?

NCT05775380 is sponsored by University of Campinas, Brazil.

What drugs are being tested in NCT05775380?

Interventions in NCT05775380: Pioglitazone 45 mg.

What condition does NCT05775380 study?

NCT05775380 studies Myocardial Reperfusion Injury.

Is NCT05775380 still recruiting?

NCT05775380 is currently status unknown. Last updated 12 January 2024.

Last reviewed 2024-01-12 · How we verify

NCT05775380: PREVALENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Pioglitazone in Vascular Transcriptional Remodeling

Status unknown Phase 4 Last updated 12 January 2024

What this trial tests

Phase 4 trial testing Pioglitazone 45 mg in Myocardial Reperfusion Injury in 20 participants. Status unknown.

Timeline

15 June 2023

Primary endpoint
28 June 2024

22 December 2024

Quick facts

Lead sponsor	University of Campinas, Brazil
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	20
Start date	15 June 2023
Primary completion	28 June 2024
Estimated completion	22 December 2024
Sites	1 location across Brazil

Drugs / interventions tested

Pioglitazone 45 mg — full drug profile →

Conditions studied

Myocardial Reperfusion Injury — all drugs for Myocardial Reperfusion Injury →

Sponsor

University of Campinas, Brazil

Who can join

Adults 40 to 70, male only, with Myocardial Reperfusion Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute myocardial infarction (AMI) remains the leading cause of death worldwide. In this scenario, early coronary reperfusion is the main therapeutic strategy as it substantially reduces mortality. Paradoxically, however, reperfusion triggers additional tissue damage that accounts for about 50% of the infarcted heart mass, i.e., ischemia and reperfusion injury (IRL). In this context, sphingosine-1-phosphate (S1P) is a sphingolipid synthesized by sphingosine kinases (Sphk), carried in plasma bound to high-density lipoprotein (HDL) and released after cellular damage such as LIR. Particularly, in animal models of AMI, therapies targeting downstream S1P receptor signaling triggered by HDL/S1P are able to promote endothelial barrier functions and attenuate secondary damage to LIR. Thus, the molecular control of sphingosine kinase 1 (Sphk1) transcription during LIR in vivo or during hypoxia/reoxygenation (H/R) in vitro may represent an important mechanism for maintaining endothelial homeostasis since it promotes the generation of S1P and this may promote subsequent HDL enrichment. Thus, the role of pioglitazone hydrochloride 45mg/day for five days in volunteers undergoing coronary artery bypass grafting (BVR) will be investigated in order to verify the vascular expression of SPhk1, transcriptome and vascular proteome remodeling, as well as S1P content in HDL.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pioglitazone 45 mg

Trials testing the same drug.

NCT06922656 — Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Preven · Phase 4 · not yet recruiting
NCT05919147 — The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia · Phase 2 · active not recruiting
NCT05501483 — Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes · NA · recruiting
NCT04604223 — Effect of Pioglitazone on T2DM Patients With COVID-19 · Phase 4 · unknown
NCT04123067 — Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke · Phase 1, PHASE2 · terminated

Other recruiting trials for Myocardial Reperfusion Injury

Currently open trials in the same condition.

NCT04813159 — Remote Ischaemic Conditioning in STEMI Patients in AFRICA · NA · recruiting

Other University of Campinas, Brazil trials

Trials by the same sponsor.

NCT06929676 — Assessment of Tooth Mobility After Non-surgical Periodontal Treatment Followed by Tooth Splinting · NA · enrolling by invitation
NCT07456163 — Influence of Zirconia Abutments on Peri-Implant Tissues in Single-Tooth Restorations · NA · recruiting
NCT06884475 — Evaluation of Implantoplasty in the Treatment of Peri-Implantitis. · NA · active not recruiting
NCT06450327 — Resistant Hypertension An Open, Complicated ("Cum Plicare") or Complex ("Cum Plexus") Syndrome? · recruiting
NCT06600867 — Method for Measuring Dental Mobility and Displacement Force · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05775380 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Campinas, Brazil
Last refreshed: 12 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05775380.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing